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Abstract
At present, routine antenatal hepatitis C virus (HCV) screening is not recommended in pregnant women who do not have
known risk factors for infection. The main reason for this attitude has been the lack of effective treatment options to avoid
mother-to-child transmission (MTCT) during pregnancy or delivery. Hitherto available treatment regimens based on interferon
(IFN) and ribavirin (RBV) were associated with sometimes long-lasting and severe side-effects and thus their indication had
to be carefully evaluated. In addition, ribavirin has teratogenic and embryocidal effects and is absolutely contraindicated during
pregnancy. The situation has substantially changed with the advent of the newly available treatment regimens based on very
effective and well-tolerated direct-acting antiviral agents (DAAs). The aim of this viewpoint is to briefly analyse, using the
example of Switzerland, how recent developments in HCV therapy might impact prevention of HCV vertical transmission.
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Introduction
At present, routine antenatal hepatitis C virus (HCV) screening
is not recommended in pregnant women who do not have known
risk factors for infection. The main reason for this attitude has been
the lack of effective treatment options to avoid mother-to-child
transmission (MTCT) during pregnancy or delivery. Hitherto
available treatment regimens based on interferon (IFN) and ribavirin
(RBV) were associated with sometimes long-lasting and severe
side-effects and thus their indication had to be carefully evaluated.
In addition, ribavirin has teratogenic and embryocidal effects and
is absolutely contraindicated during pregnancy.
The situation has substantially changed with the advent of the
newly available treatment regimens based on very effective and
well-tolerated direct-acting antiviral agents (DAAs). Today, the main
advantage of knowing the pregnant women‘s HCV status is that
those with HCV can be referred for treatment after delivery and
neonates can be closely followed up to rule out vertical infection.
Importantly, HCV eradication can be achieved without using
ribavirin. Therefore, clearing HCV infection with the new DAA
regimens before subsequent pregnancies becomes a realistic
strategy to completely eradicate HCV vertical transmission in the
future. As recently shown at a London centre, routine antenatal
screening can be cost-effective [1].
Broad variation in worldwide prevalence in
pregnant women
HCV infection is a major global health issue causing acute and
chronic liver disease, which can lead to cirrhosis and hepatocellular
carcinoma. Since the implementation of routine screening of blood
products for HCV, the leading route for childhood infection is
vertical transmission. The worldwide prevalence of HCV in pregnant
women varies: 8.6% in Egypt [2], 3.6% in Benin,1.5% in Nigeria
[3] and 1.5% In France [4]. The estimated number of people in
Europe who are HCV antibody positive varies by country from 0.4%
to 5.2% [5].
Current situation in Switzerland and estimates of
vertically acquired HCV infections
Approximately 1.6% of the Swiss population is estimated to be
HCV-antibody-positive depending on age and other characteristics
of the population [6]. An estimated number of 17,939 women
are chronically infected with HCV and most of whom are of
childbearing age. A study performed in 1990–1991 showed that
0.71% of pregnant women were HCV seropositive, more than 75%
of whom had chronic HCV infection [7]. If we consider that around
80,000 deliveries take place each year in Switzerland, it is estimated
that 568 women are HCV seropositive and among them, about
450 women will have chronic infection. With a vertical HCV
transmission rate of 6% [8], 27 infants would acquire congenital
HCV per year in Switzerland. The currently available data from
the Federal Office of Public Health (FOPH) reports only between
seven and 10 HCV cases in children from 1 to14 years of age over
the last 5 years, which is less than 50% of the expected number.
It is very likely that more than half of HCV-infected newborns are
not diagnosed as their mothers are not tested during pregnancy
and their newborns are asymptomatic after delivery. Even assuming
that approximately 10–20% of perinatally infected children will
spontaneously clear HCV infection, a larger number of them will
have progressive disease that might not be diagnosed for many
years.
Adverse events during pregnancy
HCV-positive pregnant women appear to be at risk for adverse
maternal and neonatal outcomes including gestational diabetes,
pre-eclampsia, growth restriction, antepartum haemorrhage and
preterm birth [9–13]. Rates of intrahepatic cholestasis in pregnancy
are more common in HCV-RNA-positive women, reaching rates
of up to 20% [14–16]. Furthermore, infants of HCV-positive
mothers are more likely to be born with low birthweight and to
require assisted ventilation or neonatal intensive care unit
admission. These findings seem not to be influenced by maternal
intravenous drug use [12].
As liver cell necrosis in chronic HCV infection is triggered by
immunological processes, pregnancy with ‘physiological’
immunosuppression seems to have a favourable effect on liver cell
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necrosis. Several studies have shown a decrease in the level of
transaminases during the second and third trimester of pregnancy
[17,18].
Prevention of mother-to-child transmission is
not yet feasible
MTCT is the leading source of HCV infection in children [19]. As
most of these children are asymptomatic at birth and, in the
absence of universal HCV screening, the vast majority of them
remain undiagnosed. A recent meta-analysis has shown an MTCT
rate of 5.8% [20] in HCV-seropositive and RNA-positive women.
The pathophysiology is not fully understood with regards to risk
factors. Only HCV viral load and HIV co-infection are identified
as independent risk factors for vertical transmission. There is no
evidence that transmission could be reduced by elective caesarean
section or avoidance of breastfeeding. Intravenous drug use (IVDU)
seems to be another risk factor for vertical transmission [21]. Other
studies have suggested that the duration of membrane rupture,
internal fetal monitoring and vaginal lacerations are associated with
an increased transmission rate [22,23]. However, a systematic
Cochrane database review could not show any effect of elective
Caesarean section on HCV transmission rates [24].
Paediatric infection is usually mild but chronic
active infection in 30%
The majority of chronic HCV infections in childhood are benign
and asymptomatic. Nevertheless, the early stage of vertically
acquired infection is characterised by a wide range of alanine
transaminase (ALT) abnormalities [25]. The European Paediatric
Network describes three outcomes in vertically acquired HCV
infection: 20% of neonates are expected to clear the virus; 50%
will develop chronic asymptomatic infection (intermittent viraemia,
normal ALT levels); and 30% will have chronic active infection with
persistent viraemia and frequent abnormal ALT [13]. Among
children with chronic infection, progression of liver fibrosis to
cirrhosis in adolescence has been reported, which seems to be even
faster in HIV/HCV co-infected children. However, a rapid
progression to liver cirrhosis and end-stage liver disease can also
occur in HIV-negative children [19]. There are descriptions of rare
cases with hepatocellular carcinoma that will require liver
transplantation during adolescence [26,27]. Furthermore,
extrahepatic manifestations including kidney disease, vasculitis,
dermatological manifestations and autoimmunity are reported [28].
Thus, prompt diagnosis and vigilant monitoring of paediatric HCV
are justified until treatment with DAAs becomes available in
children.
Risk group-based screening during pregnancy
remains problematic
As mentioned above, an estimated 450 women chronically infected
with HCV become pregnant every year in Switzerland. Most of
them are not aware of their infection, as HCV is not routinely
screened during pregnancy. Moreover, many women do not fit
into the classical risk-group categories and thus have never been
screened. The FOPH and the Swiss Society of Obstetrics and
Gynecology recommend the testing of at-risk pregnant women
for HCV only as part of antenatal care (www.sggg.ch). Testing is
encouraged for pregnant women with a history of intravenous drug
use or those with HIV or HBV infection. Testing is also
recommended for women who have received a blood transfusion
or a solid organ transplant before July 1992 or clotting factor
concentrates before 1987. One of the major reasons for the
underdiagnosis of maternal HCV infection with current screening
strategies is probably the inaccurate self-reporting of drug use
in pregnant women at the time of antenatal care. Studies have
shown that self-reporting is an unreliable method for determining
smoking, alcohol and drug use in pregnancy as such habits are
frequently stigmatised [29,30] .
Advent of universal HCV screening in pregnancy
in the light of new treatment options
In contrast to the situation of maternal HIV infection, measures to
influence or even prevent transmission of HCV from the mother to
her newborn are unknown. Treatment regimens based on interferon
with ribavirin have limited efficacy and severe side-effects. As ribavirin
exhibits teratogenic and embryocidal effects, it is absolutely
contraindicated during pregnancy. The situation has dramatically
changed with the availability of new treatment options that became
available last year. DAA combination regimens suppress viral
replication within a few days of treatment and cure rates above 90%
can be achieved. However, the safety and efficacy of DAAs during
pregnancy have not yet been studied. Detrimental effects on fetal
development during sofosbuvir or ledipasvir treatment have not been
seen in animal models. Accordingly, the FDA has classified both
antivirals as category B. In consequence, treatment may even become
available during pregnancy as soon as these DAAs are proved to
be safe and effective in clinical trials. In Europe, both drugs remain
currently contraindicated in pregnant and nursing women (EMEA).
(www.ema.europa.eu/docs/en_GB/document_library/Other/
2014/04/WC500164417.pdf).
Universal screening during pregnancy is justified even if treatment
cannot yet be provided during pregnancy. The short (8–12 weeks)
treatment regimens offer an ideal opportunity to cure HCV before
the next pregnancy. This completely removes the risk of subsequent
HCV transmission to the newborn and dramatically reduces the
risk of liver-related complications in the mother.
Conclusion
Universal screening of HCV during pregnancy should urgently be
re-evaluated in the light of the new DAAs. Balancing the benefits
for the mother and child against additional costs for the healthcare
system remains very important. With successful treatment of the
mother, there is the potential for completely eliminating vertical
HCV transmission. At present, as treatment is not yet available
during pregnancy, only children born from subsequent pregnancies
would be protected, following antenatal diagnosis and treatment
after delivery. Linkage of HCV-infected women to hepatology care
and a well-structured follow-up of newborns as is the case for
HIV-exposed children would be essential to allow timely HCV
management and treatment for the mother and detection of
paediatric HCV infection for their children. In the near future,
treatment for HCV during pregnancy may become available and
reduce or even eliminate the risk of vertical transmission. Therefore
the discussion for introducing a universal HCV screening during
pregnancy should be on the agenda in order to reduce the HCV
burden in mothers and their children.
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